person · Reporting owner

GRYSKA DAVID W

Disclosed activity across 8 companies

Tapewire entity: 19062
SEC CIK: 0001202335

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Celcuity Inc.CELC · Entity 3991	Director	October 01, 2026	October 05, 2026
Definium Therapeutics, Inc.DFTX · Entity 3884	Director	June 11, 2026	June 15, 2026
INCYTE CORPINCY · Entity 3182	Executive Vice President, CFO	July 16, 2018	July 18, 2018
PDL BIOPHARMA, INC.PDLI · Entity 143144	Director	December 30, 2020	December 31, 2020

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Celcuity Inc.

Report date October 01, 2026 · Filed October 05, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	893	Reported balance After 2026-10-01 transaction · row 1 1 source row Row 1 · 2026-10-01 · Grant · Acquired 893 · Balance 893 F1: Represents restricted stock units that will vest upon the earlier of (i) the 2027 annual meeting of stockholders of Celcuity Inc. or (ii) April 30, 2027.

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted stock units that will vest upon the earlier of (i) the 2027 annual meeting of stockholders of Celcuity Inc. or (ii) April 30, 2027.

Definium Therapeutics, Inc.

Report date June 11, 2026 · Filed June 15, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common SharesSEC Table I · non-derivative	Direct	19,900	Reported balance After 2026-06-11 transaction · row 1 1 source row Row 1 · 2026-06-11 · Grant · Acquired 4,666 · Balance 19,900 F1: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, any unvested RSUs will vest immediately prior to the Issuer's annual meeting following the date of grant, subject the Reporting Person's continued service through the applicable vesting date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.11 · Expires 2036-06-10	Direct	19,188	Reported balance After 2026-06-11 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-11 · Grant · Acquired 19,188 · Balance 19,188 F2: The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Issuer's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, any unvested RSUs will vest immediately prior to the Issuer's annual meeting following the date of grant, subject the Reporting Person's continued service through the applicable vesting date.

F2: The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Issuer's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date.

INCYTE CORP

Report date July 16, 2018 · Filed July 18, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	10,235	Reported balance After 2018-07-16 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2018-07-16 · Tax withholding · Disposed 455 · Balance 10,235 F1: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2: Includes an aggregate of 8,026 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock.

F2: Includes an aggregate of 8,026 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

PDL BIOPHARMA, INC.

Report date December 30, 2020 · Filed December 31, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common stockSEC Table I · non-derivative	Direct	1,387	Reported balance After 2020-12-30 transaction · row 1 1 source row Row 1 · 2020-12-30 · Sale · Disposed 20,000 · Balance 1,387

Past disclosures · reporting ended (4)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

AERIE PHARMACEUTICALS INC

Report date November 21, 2022 · Filed November 21, 2022

Section 16 reporting ended · disclosed 2022-11-21. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2022-11-21 transaction · row 1 1 source row Row 1 · 2022-11-21 · Disposition to issuer · Disposed 11,495 · Balance 0 F1: Each of the reported shares of common stock of the Company (each a "Share" or, collectively, the "Shares"), including any Shares of restricted stock, was, at the Effective Time (defined below), cancelled and converted into the right to receive $15.25 in cash (the "Merger Consideration") without interest and subject to any applicable withholding taxes.
Common StockSEC Table I · non-derivative	IndirectBy the Gryska Family Trust	Reported balance After 2022-11-21 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2022-11-21 · Disposition to issuer · Disposed 1,996 · Balance 0 F1: Each of the reported shares of common stock of the Company (each a "Share" or, collectively, the "Shares"), including any Shares of restricted stock, was, at the Effective Time (defined below), cancelled and converted into the right to receive $15.25 in cash (the "Merger Consideration") without interest and subject to any applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.27 · Expires 2030-06-11	Direct	Reported balance After 2022-11-21 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-11-21 · Disposition to issuer · Disposed 7,800 · Balance 0 F2: Each stock option with a per Share exercise price that is less than the Merger Consideration was, at the Effective Time, cancelled in exchange for a cash payment equal to, for each Share underlying the stock option (without regard to vesting), the excess of the Merger Consideration over the exercise price payable per Share underlying such stock option. Any stock options with a per Share exercise price that was more than the Merger Consideration were cancelled for no consideration.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.11 · Expires 2032-06-09	Direct	Reported balance After 2022-11-21 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2022-11-21 · Disposition to issuer · Disposed 16,854 · Balance 0 F2: Each stock option with a per Share exercise price that is less than the Merger Consideration was, at the Effective Time, cancelled in exchange for a cash payment equal to, for each Share underlying the stock option (without regard to vesting), the excess of the Merger Consideration over the exercise price payable per Share underlying such stock option. Any stock options with a per Share exercise price that was more than the Merger Consideration were cancelled for no consideration.

Filing footnotes · ownership attribution and instrument terms

F1: Each of the reported shares of common stock of the Company (each a "Share" or, collectively, the "Shares"), including any Shares of restricted stock, was, at the Effective Time (defined below), cancelled and converted into the right to receive $15.25 in cash (the "Merger Consideration") without interest and subject to any applicable withholding taxes.

F2: Each stock option with a per Share exercise price that is less than the Merger Consideration was, at the Effective Time, cancelled in exchange for a cash payment equal to, for each Share underlying the stock option (without regard to vesting), the excess of the Merger Consideration over the exercise price payable per Share underlying such stock option. Any stock options with a per Share exercise price that was more than the Merger Consideration were cancelled for no consideration.

Forte Biosciences, Inc.

Report date August 27, 2026 · Filed August 27, 2026

Section 16 reporting ended · disclosed 2026-08-27. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2026-08-27 transaction · row 1 1 source row Row 1 · 2026-08-27 · Other · Disposed 5,940 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the "Merger Agreement"), by and among Forte Biosciences, Inc. ("Company"), argenx BV ("Parent"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), the shares of common stock of Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for $77.00 per share ("Merger Consideration"), net to the seller in cash, without interest, subject to any required withholding tax. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.50 · Expires 2033-01-10	Direct	Reported balance After 2026-08-27 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-08-27 · Disposition to issuer · Disposed 2,000 · Balance 0 F2: Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger. At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.00 · Expires 2033-09-19	Direct	Reported balance After 2026-08-27 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-08-27 · Disposition to issuer · Disposed 1,000 · Balance 0 F2: Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger. At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.54 · Expires 2035-03-20	Direct	Reported balance After 2026-08-27 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-08-27 · Disposition to issuer · Disposed 31,000 · Balance 0 F2: Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger. At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor.
Stock Option (right to buy)]SEC Table II · derivative / convertible security · Conversion / exercise price $8.60 · Expires 2034-08-20	Direct	Reported balance After 2026-08-27 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-08-27 · Disposition to issuer · Disposed 2,000 · Balance 0 F2: Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger. At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2026-08-27 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-08-27 · Disposition to issuer · Disposed 18,353 · Balance 0 F3: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. (the "Issuer") Common Stock. F4: Pursuant to the Merger Agreement, each outstanding restricted stock unit (a "Company RSU"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the "Merger Agreement"), by and among Forte Biosciences, Inc. ("Company"), argenx BV ("Parent"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), the shares of common stock of Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for $77.00 per share ("Merger Consideration"), net to the seller in cash, without interest, subject to any required withholding tax. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent.

F2: Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger. At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor.

F3: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. (the "Issuer") Common Stock.

F4: Pursuant to the Merger Agreement, each outstanding restricted stock unit (a "Company RSU"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger.

GW PHARMACEUTICALS PLC

Report date May 05, 2021 · Filed May 07, 2021

Section 16 reporting ended · disclosed 2021-05-07. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	0	Reported balance After 2021-05-05 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2021-05-05 · Disposition to issuer · Disposed 35,208 · Balance 0 F1: On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland ("Jazz"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz ("Bidco") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"). The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021. F2: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3: These stock options were granted with automatic vesting on exercisable date.
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	0	Reported balance After 2021-05-05 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-05-05 · Disposition to issuer · Disposed 22,464 · Balance 0 F1: On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland ("Jazz"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz ("Bidco") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"). The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021. F2: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3: These stock options were granted with automatic vesting on exercisable date.

Filing footnotes · ownership attribution and instrument terms

F1: On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland ("Jazz"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz ("Bidco") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"). The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021.

F2: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration.

F3: These stock options were granted with automatic vesting on exercisable date.

Seagen Inc.

Report date December 14, 2023 · Filed December 15, 2023

Section 16 reporting ended · disclosed 2023-12-15. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2023-12-14 transaction · row 1 1 source row Row 1 · 2023-12-14 · Disposition to issuer · Disposed 49,003 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F2: Pursuant to the Merger Agreement, at the Effective Time, each issued and outstanding share of Common Stock (other than certain excluded shares described in the Merger Agreement) was cancelled and converted automatically into the right to receive cash in an amount equal to $229.00 per share of Common Stock (the "Merger Consideration").
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.25 · Expires 2024-05-16	Direct	Reported balance After 2023-12-14 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-12-14 · Disposition to issuer · Disposed 8,750 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.94 · Expires 2025-05-15	Direct	Reported balance After 2023-12-14 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-12-14 · Disposition to issuer · Disposed 9,260 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.82 · Expires 2026-05-20	Direct	Reported balance After 2023-12-14 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-12-14 · Disposition to issuer · Disposed 9,260 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.60 · Expires 2027-05-19	Direct	Reported balance After 2023-12-14 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2023-12-14 · Disposition to issuer · Disposed 9,260 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.77 · Expires 2028-05-18	Direct	Reported balance After 2023-12-14 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2023-12-14 · Disposition to issuer · Disposed 9,260 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.38 · Expires 2029-05-20	Direct	Reported balance After 2023-12-14 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2023-12-14 · Disposition to issuer · Disposed 7,038 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $160.33 · Expires 2030-05-15	Direct	Reported balance After 2023-12-14 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2023-12-14 · Disposition to issuer · Disposed 3,171 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $147.50 · Expires 2031-05-14	Direct	Reported balance After 2023-12-14 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2023-12-14 · Disposition to issuer · Disposed 3,462 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $135.63 · Expires 2032-05-13	Direct	Reported balance After 2023-12-14 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2023-12-14 · Disposition to issuer · Disposed 3,676 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-12-14 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2023-12-14 · Disposition to issuer · Disposed 2,044 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a "Post-Signing Company RSU") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger").

Filing footnotes · ownership attribution and instrument terms

F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger").

F2: Pursuant to the Merger Agreement, at the Effective Time, each issued and outstanding share of Common Stock (other than certain excluded shares described in the Merger Agreement) was cancelled and converted automatically into the right to receive cash in an amount equal to $229.00 per share of Common Stock (the "Merger Consideration").

F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.

F4: Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a "Post-Signing Company RSU") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
November 17, 2020 Filed Nov 19, 2020 22:33 UTC	PDL BIOPHARMA, INC. PDLI · Entity 143144	SaleCommon stock	100,000	$2.40	$240,000.00	Disclosure SEC source: 0000882104-20-000183 · wf-form4_160582519028728.xml · nonDerivative · entry 1 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,337 Read SEC document
November 05, 2020 Filed Nov 6, 2020 19:53 UTC	Seagen Inc. SGEN · Entity 13956	SaleCommon Stock	4,500	$180.60	$812,699.10	Disclosure SEC source: 0001203311-20-000128 · edgardoc.xml · nonDerivative · entry 1 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,848 F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
September 14, 2020 Filed Sep 16, 2020 20:02 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	GrantShare Options · Derivative	35,208	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-20-025421 · doc4.xml · derivative · entry 1 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,208 Underlying: Ordinary Shares · 35,208 shares Expires not disclosed F1 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest and be automatically exercised on September 14, 2023 assuming continued service. F1 · kind: Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest and be automatically exercised on September 14, 2023 assuming continued service. F1 · derivative.expiration_date: Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest and be automatically exercised on September 14, 2023 assuming continued service. Read SEC document
August 19, 2020 Filed Aug 24, 2020 10:05 UTC	PDL BIOPHARMA, INC. PDLI · Entity 143144	GrantStock Option (right to buy) · Derivative	118,671	$3.63 Strike: $3.63	$430,775.73	Disclosure SEC source: 0000882104-20-000132 · wf-form4_159826346185987.xml · derivative · entry 2 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,671 Underlying: Common stock · 118,671 shares Expires 2030-08-19 F2 · derivative.exercise_date: The stock options will vest on the one year anniversary of the grant date, subject to acceleration of vesting upon a change in control or the Company filing a certificate of dissolution with the state of Delaware; provided that the recipient's continuous service has not terminated prior to such date. Read SEC document
August 19, 2020 Filed Aug 24, 2020 10:05 UTC	PDL BIOPHARMA, INC. PDLI · Entity 143144	GrantCommon stock	25,826	$0.00	$0.00	Disclosure SEC source: 0000882104-20-000132 · wf-form4_159826346185987.xml · nonDerivative · entry 1 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,337 F1 · shares: The restricted stock will vest on the one year anniversary of the grant date, subject to acceleration of vesting upon a change in control or the Company filing a certificate of dissolution with the state of Delaware; provided that the recipient's continuous service has not terminated prior to such date. Read SEC document
June 11, 2020 Filed Jun 30, 2020 00:03 UTC	AERIE PHARMACEUTICALS INC AERI · Entity 122210	GrantStock Option (right to buy) · Derivative	7,800	$0.00 Strike: $13.27	$0.00	Disclosure SEC source: 0001209191-20-039261 · doc4.xml · derivative · entry 3 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,800 Underlying: Common Stock · 7,800 shares Expires 2030-06-11 F2 · derivative.exercise_date: Subject to the reporting person's continued service on the board of directors of the issuer through the applicable vesting date, this option is scheduled to vest ratably on each of the first 12 monthly anniversaries of June 11, 2020. Read SEC document
June 11, 2020 Filed Jun 30, 2020 00:03 UTC	AERIE PHARMACEUTICALS INC AERI · Entity 122210	GrantCommon Stock	1,750	$0.00	$0.00	Disclosure SEC source: 0001209191-20-039261 · doc4.xml · nonDerivative · entry 1 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 F1 · shares: Subject to the reporting person's continued service on the board of directors of the issuer through the vesting date, these shares of Common Stock are scheduled to vest on June 11, 2021. Read SEC document
May 15, 2020 Filed May 19, 2020 19:10 UTC	Seagen Inc. SGEN · Entity 13956	GrantNon-Qualified Stock Option (right to buy) · Derivative	3,171	$0.00 Strike: $160.33	$0.00	Disclosure SEC source: 0001203311-20-000047 · edgardoc.xml · derivative · entry 2 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,171 Underlying: Common Stock · 3,171 shares Expires 2030-05-15 Read SEC document
May 15, 2020 Filed May 19, 2020 19:10 UTC	Seagen Inc. SGEN · Entity 13956	GrantCommon Stock	1,335	$0.00	$0.00	Disclosure SEC source: 0001203311-20-000047 · edgardoc.xml · nonDerivative · entry 1 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,348 F1 · security: These restricted stock units will be settled in common stock upon vesting. F2 · date: These restricted stock units shall vest in full on May 15, 2021. F3 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
October 01, 2019 Filed Oct 3, 2019 19:38 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	2,500	$0.00 Strike: $19.02	$0.00	Disclosure SEC source: 0001203311-19-000053 · edgardoc.xml · derivative · entry 6 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 2,500 shares Expires 2021-05-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Options were fully vested on 5/20/12. Read SEC document
October 01, 2019 Filed Oct 3, 2019 19:38 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	2,500	$0.00 Strike: $12.76	$0.00	Disclosure SEC source: 0001203311-19-000053 · edgardoc.xml · derivative · entry 5 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires 2020-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Options were fully vested on 5/20/11. Read SEC document
October 01, 2019 Filed Oct 3, 2019 19:38 UTC	Seagen Inc. SGEN · Entity 13956	SaleCommon Stock	2,500	$84.85	$212,125.00	Disclosure SEC source: 0001203311-19-000053 · edgardoc.xml · nonDerivative · entry 4 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,013 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $84.32 to $85.00. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
October 01, 2019 Filed Oct 3, 2019 19:38 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionCommon Stock	2,500	$12.76	$31,900.00	Disclosure SEC source: 0001203311-19-000053 · edgardoc.xml · nonDerivative · entry 3 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,513 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
October 01, 2019 Filed Oct 3, 2019 19:38 UTC	Seagen Inc. SGEN · Entity 13956	SaleCommon Stock	2,500	$85.33	$213,325.00	Disclosure SEC source: 0001203311-19-000053 · edgardoc.xml · nonDerivative · entry 2 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,013 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $85.00 to $85.60. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
October 01, 2019 Filed Oct 3, 2019 19:38 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionCommon Stock	2,500	$19.02	$47,550.00	Disclosure SEC source: 0001203311-19-000053 · edgardoc.xml · nonDerivative · entry 1 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,513 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
July 17, 2019 Filed Jul 19, 2019 18:20 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	5,000	$0.00 Strike: $12.76	$0.00	Disclosure SEC source: 0001203311-19-000028 · edgardoc.xml · derivative · entry 3 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 5,000 shares Expires 2020-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Options were fully vested on 5/20/11. Read SEC document
July 17, 2019 Filed Jul 19, 2019 18:20 UTC	Seagen Inc. SGEN · Entity 13956	SaleCommon Stock	5,000	$75.00	$375,000.00	Disclosure SEC source: 0001203311-19-000028 · edgardoc.xml · nonDerivative · entry 2 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,013 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $75.00 to $75.02. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
July 17, 2019 Filed Jul 19, 2019 18:20 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionCommon Stock	5,000	$12.76	$63,800.00	Disclosure SEC source: 0001203311-19-000028 · edgardoc.xml · nonDerivative · entry 1 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,013 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
June 20, 2019 Filed Jun 25, 2019 01:38 UTC	PDL BIOPHARMA, INC. PDLI · Entity 143144	GrantStock Option (right to buy) · Derivative	126,050	$3.00 Strike: $3.00	$378,150.00	Disclosure SEC source: 0000882104-19-000071 · wf-form4_156142669342434.xml · derivative · entry 1 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,050 Underlying: Common stock · 126,050 shares Expires 2029-06-19 F1 · derivative.exercise_date: The stock options shall vest on a monthly basis pro rata over the twelve (12) months following the grant date, provided that the recipient's continuous service has not terminated prior to the applicable vesting date. Read SEC document
May 23, 2019 Filed May 23, 2019 22:11 UTC	AERIE PHARMACEUTICALS INC AERI · Entity 122210	GrantStock Option (right to buy) · Derivative	7,800	$0.00 Strike: $39.44	$0.00	Disclosure SEC source: 0001209191-19-032432 · doc4.xml · derivative · entry 3 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,800 Underlying: Common Stock · 7,800 shares Expires 2029-05-23 F2 · derivative.exercise_date: Subject to the reporting person's continued service on the board of directors of the issuer through the applicable vesting date, this option is scheduled to vest ratably on each of the first 12 monthly anniversaries of May 23, 2019. Read SEC document
May 23, 2019 Filed May 23, 2019 22:11 UTC	AERIE PHARMACEUTICALS INC AERI · Entity 122210	GrantCommon Stock	1,750	$0.00	$0.00	Disclosure SEC source: 0001209191-19-032432 · doc4.xml · nonDerivative · entry 1 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,750 F1 · shares: Subject to the reporting person's continued service on the board of directors of the issuer through the vesting date, these shares of Common Stock are scheduled to vest on May 23, 2020. Read SEC document
May 20, 2019 Filed May 22, 2019 21:39 UTC	Seagen Inc. SGEN · Entity 13956	GrantNon-Qualified Stock Option (right to buy) · Derivative	7,038	$0.00 Strike: $64.38	$0.00	Disclosure SEC source: 0000899243-19-014434 · doc4.xml · derivative · entry 2 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,038 Underlying: Common Stock · 7,038 shares Expires 2029-05-20 F3 · derivative.exercise_date: These options shall vest in full on May 20, 2020. Read SEC document
May 20, 2019 Filed May 22, 2019 21:39 UTC	Seagen Inc. SGEN · Entity 13956	GrantCommon Stock	2,963	$0.00	$0.00	Disclosure SEC source: 0000899243-19-014434 · doc4.xml · nonDerivative · entry 1 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,013 F1 · security: These restricted stock units will be settled in common stock upon vesting. F2 · date: These restricted stock units shall vest in full on May 20, 2020. Read SEC document
April 01, 2019 Filed Apr 3, 2019 20:57 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	5,000	$0.00 Strike: $12.76	$0.00	Disclosure SEC source: 0001203311-19-000015 · edgardoc.xml · derivative · entry 4 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 5,000 shares Expires 2020-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vested in full on May 20, 2011. Read SEC document
April 01, 2019 Filed Apr 3, 2019 20:57 UTC	Seagen Inc. SGEN · Entity 13956	SaleCommon Stock	206	$74.01	$15,246.06	Disclosure SEC source: 0001203311-19-000015 · edgardoc.xml · nonDerivative · entry 3 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,050 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $74.00 to $74.24. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
April 01, 2019 Filed Apr 3, 2019 20:57 UTC	Seagen Inc. SGEN · Entity 13956	SaleCommon Stock	4,794	$73.38	$351,783.72	Disclosure SEC source: 0001203311-19-000015 · edgardoc.xml · nonDerivative · entry 2 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,256 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $73.00 to $73.99. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
April 01, 2019 Filed Apr 3, 2019 20:57 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionCommon Stock	5,000	$12.76	$63,800.00	Disclosure SEC source: 0001203311-19-000015 · edgardoc.xml · nonDerivative · entry 1 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,050 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
January 08, 2019 Filed Jan 10, 2019 21:09 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	5,000	$0.00 Strike: $12.76	$0.00	Disclosure SEC source: 0001203311-19-000004 · edgardoc.xml · derivative · entry 3 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 5,000 shares Expires 2020-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested in full on May 20, 2011. Read SEC document
January 08, 2019 Filed Jan 10, 2019 21:09 UTC	Seagen Inc. SGEN · Entity 13956	SaleCommon Stock	5,000	$65.04	$325,200.00	Disclosure SEC source: 0001203311-19-000004 · edgardoc.xml · nonDerivative · entry 2 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,050 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $65.00 to $65.10. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F3 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
January 08, 2019 Filed Jan 10, 2019 21:09 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionCommon Stock	5,000	$12.76	$63,800.00	Disclosure SEC source: 0001203311-19-000004 · edgardoc.xml · nonDerivative · entry 1 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,050 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 12, 2018 Filed Sep 12, 2018 21:14 UTC	AERIE PHARMACEUTICALS INC AERI · Entity 122210	GrantStock Option (right to buy) · Derivative	25,000	$0.00 Strike: $58.35	$0.00	Disclosure SEC source: 0001209191-18-050663 · doc4.xml · derivative · entry 1 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-09-12 F1 · derivative.exercise_date: Subject to the reporting person's continued service on the board of directors of the issuer through the applicable vesting date, this option is scheduled to vest ratably over a three-year period on each of the first 12 quarterly anniversaries of September 12, 2018. Read SEC document
July 16, 2018 Filed Jul 18, 2018 20:12 UTC	INCYTE CORP INCY · Entity 3182	Tax withholdingCommon Stock	455	$70.19	$31,936.45	Disclosure SEC source: 0001209191-18-043028 · doc4.xml · nonDerivative · entry 1 GRYSKA DAVID W · CIK 0001202335 · Executive Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,235 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: Includes an aggregate of 8,026 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document
July 05, 2018 Filed Jul 5, 2018 21:12 UTC	INCYTE CORP INCY · Entity 3182	Tax withholdingCommon Stock	280	$68.28	$19,118.40	Disclosure SEC source: 0001209191-18-041743 · doc4.xml · nonDerivative · entry 1 GRYSKA DAVID W · CIK 0001202335 · Executive Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,690 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: Includes an aggregate of 9,415 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document
July 02, 2018 Filed Jul 5, 2018 21:12 UTC	INCYTE CORP INCY · Entity 3182	GrantEmployee Stock Option (right to buy) · Derivative	22,772	$0.00 Strike: $68.62	$0.00	Disclosure SEC source: 0001209191-18-041743 · doc4.xml · derivative · entry 2 GRYSKA DAVID W · CIK 0001202335 · Executive Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,772 Underlying: Common Stock · 22,772 shares Expires 2028-07-01 F3 · derivative.exercise_date: Beginning July 2, 2018, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document
June 08, 2018 Filed Jun 12, 2018 20:28 UTC	PDL BIOPHARMA, INC. PDLI · Entity 143144	GrantCommon stock	54,348	$2.76	$150,000.48	Disclosure SEC source: 0000882104-18-000065 · wf-form4_152883531931399.xml · nonDerivative · entry 1 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,511 F1 · shares: The grant will cliff-vest on the first anniversary of the date of grant so long as the grant recipient continues to serve on the Board of Directors of PDL BioPharma, Inc. Read SEC document
May 18, 2018 Filed May 22, 2018 20:06 UTC	Seagen Inc. SGEN · Entity 13956	GrantNon-Qualified Stock Option (right to buy) · Derivative	9,260	$0.00 Strike: $56.77	$0.00	Disclosure SEC source: 0001203311-18-000031 · edgardoc.xml · derivative · entry 2 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,260 Underlying: Common Stock · 9,260 shares Expires 2028-05-18 F3 · derivative.exercise_date: The option shall vest in full on May 18, 2019. Read SEC document
May 18, 2018 Filed May 22, 2018 20:06 UTC	Seagen Inc. SGEN · Entity 13956	GrantCommon Stock	3,700	$0.00	$0.00	Disclosure SEC source: 0001203311-18-000031 · edgardoc.xml · nonDerivative · entry 1 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,050 F1 · security: These shares represent restricted stock units and will be settled in common stock upon vesting. F2 · deemedExecutionDate: Restricted stock units shall vest in full on May 18, 2019. Read SEC document
February 21, 2018 Filed Feb 22, 2018 21:46 UTC	INCYTE CORP INCY · Entity 3182	SaleCommon Stock	1,952	$85.56	$167,013.12	Disclosure SEC source: 0001209191-18-012484 · doc4.xml · nonDerivative · entry 2 GRYSKA DAVID W · CIK 0001202335 · Executive Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,970 F2 · shares: Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated. F3 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F4 · shares: Represents weighted average sale price. Actual sale prices ranged from $85.11 - $86.28. F5 · balance_after: Includes an aggregate of 10,294 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document
February 20, 2018 Filed Feb 22, 2018 21:46 UTC	INCYTE CORP INCY · Entity 3182	Tax withholdingCommon Stock	1,070	$86.03	$92,052.10	Disclosure SEC source: 0001209191-18-012484 · doc4.xml · nonDerivative · entry 1 GRYSKA DAVID W · CIK 0001202335 · Executive Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,922 F1 · shares: Represents shares withheld to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. Read SEC document
January 23, 2018 Filed Jan 25, 2018 21:33 UTC	INCYTE CORP INCY · Entity 3182	GrantEmployee Stock Option (right to buy) · Derivative	12,128	$0.00 Strike: $94.63	$0.00	Disclosure SEC source: 0001209191-18-005387 · doc4.xml · derivative · entry 1 GRYSKA DAVID W · CIK 0001202335 · Executive Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,128 Underlying: Common Stock · 12,128 shares Expires 2028-01-22 F1 · derivative.exercise_date: Beginning January 23, 2018, options become exercisable in 37 installments, with the first 25.00% vesting on July 5, 2018 and the remainder vesting monthly over three years. Read SEC document
January 05, 2018 Filed Jan 9, 2018 21:09 UTC	INCYTE CORP INCY · Entity 3182	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	6,760	$0.00 Strike: $83.83	$0.00	Disclosure SEC source: 0001209191-18-002909 · doc4.xml · derivative · entry 3 GRYSKA DAVID W · CIK 0001202335 · Executive Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,735 Underlying: Common Stock · 6,760 shares Expires 2026-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Beginning July 15, 2016, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document
January 05, 2018 Filed Jan 9, 2018 21:09 UTC	INCYTE CORP INCY · Entity 3182	SaleCommon Stock	6,760	$98.87	$668,361.20	Disclosure SEC source: 0001209191-18-002909 · doc4.xml · nonDerivative · entry 2 GRYSKA DAVID W · CIK 0001202335 · Executive Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,992 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · price: Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated. F3 · price: Represents weighted average sale price. Actual sale prices ranged from $98.56 - $99.39. F4 · balance_after: This includes an aggregate of 13,316 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document
January 05, 2018 Filed Jan 9, 2018 21:09 UTC	INCYTE CORP INCY · Entity 3182	Exercise / conversionCommon Stock	6,760	$83.83	$566,690.80	Disclosure SEC source: 0001209191-18-002909 · doc4.xml · nonDerivative · entry 1 GRYSKA DAVID W · CIK 0001202335 · Executive Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,752 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 02, 2017 Filed Nov 3, 2017 20:01 UTC	INCYTE CORP INCY · Entity 3182	SaleCommon Stock	3,915	$105.63	$413,541.45	Disclosure SEC source: 0001209191-17-059139 · doc4.xml · nonDerivative · entry 2 GRYSKA DAVID W · CIK 0001202335 · Executive Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,992 F2 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F3 · price: Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated. F4 · price: Represents weighted average sale price. Actual sale prices ranged from $104.51 - $107.74. F5 · balance_after: Includes an aggregate of 13,316 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document
November 01, 2017 Filed Nov 3, 2017 20:01 UTC	INCYTE CORP INCY · Entity 3182	Tax withholdingCommon Stock	3,913	$107.96	$422,447.48	Disclosure SEC source: 0001209191-17-059139 · doc4.xml · nonDerivative · entry 1 GRYSKA DAVID W · CIK 0001202335 · Executive Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,907 F1 · shares: Represents shares withheld to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. Read SEC document
September 13, 2017 Filed Sep 15, 2017 20:14 UTC	INCYTE CORP INCY · Entity 3182	Tax withholdingCommon Stock	712	$123.15	$87,682.80	Disclosure SEC source: 0001209191-17-052957 · doc4.xml · nonDerivative · entry 1 GRYSKA DAVID W · CIK 0001202335 · Executive Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,820 F1 · shares: Represents shares withheld to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: Includes an aggregate of 21,144 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document
July 05, 2017 Filed Jul 7, 2017 20:56 UTC	INCYTE CORP INCY · Entity 3182	GrantIncentive Stock Option (right to buy) · Derivative	779	$0.00 Strike: $128.34	$0.00	Disclosure SEC source: 0001209191-17-044420 · doc4.xml · derivative · entry 3 GRYSKA DAVID W · CIK 0001202335 · Executive Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 779 Underlying: Common Stock · 779 shares Expires 2027-07-04 F3 · derivative.exercise_date: Beginning July 5, 2017, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document
July 05, 2017 Filed Jul 7, 2017 20:56 UTC	INCYTE CORP INCY · Entity 3182	GrantNon-Qualified Stock Option (right to buy) · Derivative	11,349	$0.00 Strike: $128.34	$0.00	Disclosure SEC source: 0001209191-17-044420 · doc4.xml · derivative · entry 2 GRYSKA DAVID W · CIK 0001202335 · Executive Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,349 Underlying: Common Stock · 11,349 shares Expires 2027-07-04 F3 · derivative.exercise_date: Beginning July 5, 2017, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document
July 05, 2017 Filed Jul 7, 2017 20:56 UTC	INCYTE CORP INCY · Entity 3182	GrantCommon Stock	3,517	$0.00	$0.00	Disclosure SEC source: 0001209191-17-044420 · doc4.xml · nonDerivative · entry 1 GRYSKA DAVID W · CIK 0001202335 · Executive Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,532 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Mr. Gryska's continued service with the Issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Includes an aggregate of 19,015 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document
June 30, 2017 Filed Jul 5, 2017 20:12 UTC	INCYTE CORP INCY · Entity 3182	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	599	$0.00 Strike: $73.21	$0.00	Disclosure SEC source: 0001209191-17-043277 · doc4.xml · derivative · entry 3 GRYSKA DAVID W · CIK 0001202335 · Executive Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,591 Underlying: Common Stock · 599 shares Expires 2022-01-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Beginning January 8, 2015, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.